Michael Barbella, Managing Editor09.07.23
HippoFi Inc. is partnering with Zimmer Biomet Holdings Inc. to introduce a synthetic bone growth biomaterial next year.
The product will be released through HippoFi's biologic subsidiary, PUR Biologics, a developer of regenerative medicine solutions. "Our collaboration with Zimmer Biomet is a significant stride in our journey to elevate the standards of patient care. We're excited to bring this innovative technology to the forefront of spinal treatments," PUR Biologics Head Ryan Fernan said.
HippoFi/PUR has received U.S. Food and Drug Administration 510(K) clearance for ActiveOrbTM technology, while also securing from Zimmer Biomet an exclusive global license to the underlying technology for the spine market. Both entities have also engaged in a joint commercialization research agreement, with Zimmer Biomet overseeing production of the spine-specific product under the PUR Biologics brand.
"Joining forces with Zimmer Biomet not only amplifies our reach, but also reinforces our commitment to delivering breakthrough biologics that transform lives," HippoFi CEO C.J. Wiggins stated.
PUR Biologics, a wholly owned subsidiary of HippoFi Inc., offers biologic products that include advanced allografts and demineralized extracellular matrices (d-ECM), synthetic bone-forming solutions, cellular-derived tissues, and a future of patented and next-generation regenerative stem cell and growth factor-driven therapeutics for treating osteoarthritis and cartilage regeneration.
HippoFi Inc. delivers its healthcare innovations and propriety technologies through an extensive sales channel network, while implementing solutions in the multibillion-dollar biotech, fintech, and artificial intelligence (AI) markets. HippoFi comprises three segments: Regenerative Therapeutics, Digital Payments, and AI, and utilizes the same customer channels to commercialize solutions, drive revenue, and improve patient outcomes. HippoFi is headquartered in Irvine, Calif.
The product will be released through HippoFi's biologic subsidiary, PUR Biologics, a developer of regenerative medicine solutions. "Our collaboration with Zimmer Biomet is a significant stride in our journey to elevate the standards of patient care. We're excited to bring this innovative technology to the forefront of spinal treatments," PUR Biologics Head Ryan Fernan said.
HippoFi/PUR has received U.S. Food and Drug Administration 510(K) clearance for ActiveOrbTM technology, while also securing from Zimmer Biomet an exclusive global license to the underlying technology for the spine market. Both entities have also engaged in a joint commercialization research agreement, with Zimmer Biomet overseeing production of the spine-specific product under the PUR Biologics brand.
"Joining forces with Zimmer Biomet not only amplifies our reach, but also reinforces our commitment to delivering breakthrough biologics that transform lives," HippoFi CEO C.J. Wiggins stated.
PUR Biologics, a wholly owned subsidiary of HippoFi Inc., offers biologic products that include advanced allografts and demineralized extracellular matrices (d-ECM), synthetic bone-forming solutions, cellular-derived tissues, and a future of patented and next-generation regenerative stem cell and growth factor-driven therapeutics for treating osteoarthritis and cartilage regeneration.
HippoFi Inc. delivers its healthcare innovations and propriety technologies through an extensive sales channel network, while implementing solutions in the multibillion-dollar biotech, fintech, and artificial intelligence (AI) markets. HippoFi comprises three segments: Regenerative Therapeutics, Digital Payments, and AI, and utilizes the same customer channels to commercialize solutions, drive revenue, and improve patient outcomes. HippoFi is headquartered in Irvine, Calif.